Lv51
870 积分 2023-03-20 加入
Are Doses to ICRU Reference Points Valuable for Predicting Late Rectal and Bladder Morbidity after Definitive Radiotherapy in Uterine Cervix Cancer?
13分钟前
已完结
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
3个月前
已完结
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
3个月前
已完结
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
3个月前
已完结
Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline
3个月前
已完结
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial
3个月前
已完结
1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain
3个月前
已完结
P3.18.76 Efficacy and Safety of Cross-Line Adebrelimab Combined With Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer
3个月前
已关闭
EP.18.09 Adebrelimab Beyond Progression Plus Chemotherapy or Targeted Therapy as Second-Line Treatment for Extensive-Stage Small Cell Lung Cancer
3个月前
已关闭
Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis
3个月前
已完结